KKQ8 Antibody

What is KRT8 and why is it important in cellular research?

KRT8 (Cytokeratin 8) is a type II intermediate filament protein expressed primarily in simple epithelial cells and serves as a critical structural component of the cytoskeleton. Together with KRT19, it helps link the contractile apparatus to dystrophin at the costameres of striated muscle . Its importance in research stems from its role as a biomarker for epithelial differentiation, its involvement in cellular stress responses, and its significance in cancer diagnostics. KRT8 is frequently used to identify cells of epithelial origin and has been implicated in various carcinomas, making KRT8 antibodies essential tools for both basic research and clinical applications .

What are the common applications for KRT8 antibodies?

KRT8 antibodies are utilized across multiple experimental platforms:

The versatility of KRT8 antibodies makes them valuable for studying epithelial biology, cancer pathology, and cellular stress responses . These applications allow researchers to track KRT8 expression, localization, and post-translational modifications in various experimental contexts.

How do I select the appropriate KRT8 antibody for my experiment?

Selection of the appropriate KRT8 antibody depends on several factors:

• Specificity: Determine whether you need an antibody specific only to KRT8 or one that recognizes both KRT8 and KRT18 (which often dimerize). Some antibodies like C51 detect both KRT8 and KRT18, while others are KRT8-specific .

• Species reactivity: Verify cross-reactivity with your species of interest. Available antibodies have different reactivity profiles, with many optimized for human samples but some also recognizing monkey or other mammalian KRT8 .

• Application compatibility: Ensure the antibody is validated for your specific application (WB, IHC, IF, etc.). Some antibodies perform well across multiple applications, while others are optimized for specific techniques .

• Clonality: Consider whether a monoclonal or polyclonal antibody better suits your needs. Monoclonal antibodies offer higher specificity but recognize single epitopes, while polyclonal antibodies provide signal amplification but may have more background 3.

• Validation data: Review available validation data, particularly knockout validation studies which provide the strongest evidence for specificity3.

What controls should I include when using KRT8 antibodies?

Proper controls are critical for reliable KRT8 antibody experiments:

• Positive tissue/cell controls: Include samples known to express KRT8, such as MCF7 cells or epithelial tissues like colon or prostate .

• Negative controls: Include tissues known not to express KRT8 (e.g., lymphoid tissues) or isotype controls to assess non-specific binding.

• Knockout/knockdown controls: When available, use KRT8 knockout cell lysates as the gold standard negative control. These provide definitive evidence of antibody specificity3.

• Loading controls: For Western blots, include appropriate loading controls (β-actin, GAPDH) to ensure equal protein loading across samples3.

• Secondary antibody controls: Include samples treated only with secondary antibody to detect non-specific binding or autofluorescence.

The inclusion of these controls helps validate results and troubleshoot potential issues with antibody specificity or experimental conditions3.

How can I validate KRT8 antibody specificity in my experimental system?

Validating antibody specificity is crucial for reliable results. A comprehensive validation approach includes:

• Knockout/knockdown validation: The gold standard approach involves comparing signal between wild-type samples and those where KRT8 has been knocked out (CRISPR) or knocked down (siRNA). A specific antibody will show decreased or absent signal in KO/KD samples3.

• Peptide competition assays: Pre-incubate your antibody with excess immunizing peptide before staining. Specific binding should be blocked, eliminating signal.

• Multiple antibody approach: Use antibodies targeting different epitopes of KRT8. Consistent results across different antibodies increase confidence in specificity.

• Mass spectrometry validation: Immunoprecipitate with your KRT8 antibody and analyze by mass spectrometry to confirm target identity.

• Cross-species reactivity testing: If KRT8 is conserved across species of interest, consistent detection patterns support specificity.

The most rigorous approach involves knockout lysate validation, where cell lines with both alleles of KRT8 knocked out by CRISPR are compared with parental controls. A specific antibody will detect the target in the parental line but show no signal in the knockout line3.

What are the key considerations when using KRT8 antibodies for cancer research?

When applying KRT8 antibodies in cancer research, consider these critical factors:

• Expression heterogeneity: KRT8 expression varies across cancer types and even within tumors. Simple epithelial tumors (adenocarcinomas) typically express KRT8/18, while squamous cell carcinomas may show different keratin profiles .

• Post-translational modifications: KRT8 undergoes phosphorylation, glycosylation, and other modifications that may affect antibody binding and biological function. Consider using modification-specific antibodies for detailed studies.

• Circulating KRT8: Released from dying tumor cells, circulating KRT8 and anti-KRT8 antibodies have been detected in cancer patients' serum, potentially serving as biomarkers .

• Co-expression analysis: KRT8 is typically co-expressed with KRT18 as its obligate heterodimer partner. Analyzing both provides more comprehensive information about epithelial status and differentiation.

• Tissue context: Interpret KRT8 expression in the proper tissue context. Aberrant expression in tissues that normally lack KRT8 may indicate pathological processes.

Research has shown that KRT8-specific autoantibodies can be elevated in patients with head and neck cancer, suggesting potential utility as serological tumor markers . This underscores the importance of considering both the cellular expression of KRT8 and potential immune responses against it in cancer studies.

How do I troubleshoot inconsistent results with KRT8 antibodies in immunohistochemistry?

Inconsistent immunohistochemistry results can stem from multiple factors:

• Fixation variables:

  • Overfixation can mask epitopes

  • Underfixation may cause tissue degradation

  • Solution: Optimize fixation time (typically 24-48 hours in 10% neutral buffered formalin) and perform antigen retrieval

• Antigen retrieval issues:

  • Inadequate epitope unmasking

  • Solution: Test different methods (citrate buffer pH 6.0 vs. EDTA pH 9.0) and times (10-20 minutes)

• Antibody concentration:

  • Too high: background staining

  • Too low: false negatives

  • Solution: Perform titration experiments (1:25, 1:50, 1:100, 1:200)

• Detection system sensitivity:

  • Solution: Compare DAB vs. amplification systems for low-expression samples

• Tissue processing artifacts:

  • Solution: Ensure consistent dehydration/clearing/embedding protocols

A methodical approach to troubleshooting involves systematically altering one variable at a time while maintaining proper controls. For particularly challenging samples, consider dual staining with another epithelial marker to confirm tissue integrity and cell type .

What is the significance of KRT8/KRT18 co-detection versus KRT8-specific detection?

The decision to detect KRT8 alone or in combination with KRT18 has important research implications:

• Biological relevance: KRT8 and KRT18 form obligate heterodimers in cells, functioning as a unit in intermediate filament formation. Co-detection may provide more biologically relevant information about the functional cytoskeleton .

• Diagnostic applications: In cancer diagnostics, the KRT8/18 pair is often more informative than either keratin alone, helping distinguish adenocarcinomas from other tumor types.

• Technical considerations:

  • KRT8/KRT18 dual antibodies (like C51) detect both proteins simultaneously, potentially providing stronger signal

  • KRT8-specific antibodies allow precise quantification of KRT8 independent of KRT18 levels

• Research questions: Choose based on your specific question:

  • Studying keratin filament integrity: use dual detection

  • Investigating KRT8-specific functions or modifications: use KRT8-specific antibodies

  • Examining stoichiometric relationships: use separate antibodies for each

Studies have shown that while KRT8 and KRT18 are typically co-expressed, their ratios can vary in different physiological and pathological states. KRT8-specific detection allows researchers to examine these variations, which may have functional significance in cellular stress responses and cancer progression .

What is the optimal protocol for Western blotting using KRT8 antibodies?

An optimized Western blotting protocol for KRT8 detection includes:

• Sample preparation:

  • Lyse cells in RIPA buffer supplemented with protease inhibitors

  • Include phosphatase inhibitors if studying phosphorylated KRT8

  • Heat samples at 95°C for 5 minutes in Laemmli buffer with 5% β-mercaptoethanol

• Gel electrophoresis:

  • Use 10% SDS-PAGE gels for optimal resolution

  • Load 10-30 μg total protein per lane

  • Include positive control (epithelial cell lysate) and molecular weight marker

• Transfer:

  • Transfer to PVDF membrane at 100V for 1 hour or 30V overnight

  • Verify transfer with Ponceau S staining

• Blocking and antibody incubation:

  • Block in 5% non-fat milk in TBST for 1 hour at room temperature

  • Incubate with primary KRT8 antibody (1:1000 dilution) overnight at 4°C

  • Wash 3× with TBST (10 minutes each)

  • Incubate with HRP-conjugated secondary antibody (1:5000) for 1 hour at room temperature

  • Wash 3× with TBST (10 minutes each)

• Detection:

  • Develop using ECL substrate

  • Expect bands at approximately 55 kDa for KRT8 and 46 kDa for KRT18 (if using a dual antibody)

This protocol consistently produces clean, specific bands with minimal background when using validated KRT8 antibodies. For challenging samples, consider longer blocking times or different blocking agents (BSA instead of milk) .

How can I optimize immunofluorescence staining with KRT8 antibodies?

For optimal immunofluorescence results with KRT8 antibodies:

• Cell fixation options:

  • 4% paraformaldehyde (10 minutes, room temperature) for structure preservation

  • 100% ice-cold methanol (5 minutes) for enhanced epitope accessibility

  • Compare both methods as epitope accessibility can vary

• Permeabilization (for PFA-fixed cells):

  • 0.1-0.2% Triton X-100 in PBS for 10 minutes

  • Alternative: 0.5% saponin for gentler permeabilization

• Blocking:

  • 1% BSA, 10% normal serum (from secondary antibody host species), 0.3M glycine in 0.1% PBS-Tween for 1 hour

  • Include 0.1-0.3M glycine to quench free aldehyde groups

• Antibody incubation:

  • Primary: Use KRT8 antibody at 1:50-1:100 dilution, overnight at 4°C

  • Secondary: Fluorophore-conjugated secondary at 1:1000, 1 hour at room temperature

  • Include DAPI (1:1000) for nuclear counterstaining

• Mounting and imaging:

  • Use anti-fade mounting medium

  • Image using confocal microscopy for optimal filament structure visualization

For co-staining with other cytoskeletal markers, select antibodies raised in different host species to avoid cross-reactivity. A successful KRT8 staining should reveal a filamentous network throughout the cytoplasm, often with perinuclear concentration in epithelial cells .

What approaches can detect the interaction between KRT8 and other proteins?

To investigate KRT8 protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Lyse cells in non-denaturing buffer to preserve protein complexes

  • Immunoprecipitate using anti-KRT8 antibody bound to protein A/G beads

  • Western blot for suspected interacting partners

  • Validate with reverse Co-IP (immunoprecipitate partner, blot for KRT8)

• Proximity Ligation Assay (PLA):

  • Fixed cells are incubated with primary antibodies against KRT8 and potential partner

  • Secondary antibodies with attached oligonucleotides enable amplification when proteins are <40nm apart

  • Produces fluorescent spots where proteins interact

  • Advantage: Visualizes interactions in situ with subcellular resolution

• FRET (Förster Resonance Energy Transfer):

  • Express KRT8 and partner protein tagged with compatible fluorophores

  • Energy transfer occurs only when proteins are in close proximity (<10nm)

  • Requires specialized microscopy setup

  • Advantage: Can detect dynamic interactions in living cells

• Mass spectrometry-based approaches:

  • Immunoprecipitate KRT8 complexes

  • Digest and analyze by LC-MS/MS

  • Advantage: Unbiased discovery of novel interactions

• Yeast two-hybrid screening:

  • Use KRT8 as bait to screen for interacting partners

  • Validate hits with above methods in mammalian cells

Each approach has strengths and limitations. Co-IP is straightforward but may miss weak or transient interactions, while PLA and FRET provide spatial information but require specialized equipment. Using multiple complementary methods strengthens confidence in identified interactions .

How can I distinguish between true and false positive signals when using KRT8 antibodies?

Distinguishing genuine KRT8 signals from artifacts requires a systematic approach:

• Pattern recognition:

  • True KRT8 staining shows a filamentous cytoplasmic pattern in epithelial cells

  • Uniform or diffuse staining may indicate background

  • Nuclear staining is typically non-specific for KRT8

• Validation with multiple techniques:

  • Confirm IHC findings with Western blot or IF

  • Use different antibody clones targeting distinct epitopes

  • Compare with mRNA expression data (e.g., in situ hybridization)

• Biological logic:

  • KRT8 expression should correlate with epithelial phenotype

  • Expression should be consistent with known patterns (e.g., positive in simple epithelia, negative in mesenchymal cells)

  • Co-expression with KRT18 supports genuine detection

• Knockout/knockdown validation:

  • Signal should decrease or disappear in KRT8 knockout or knockdown samples

  • Use CRISPR knockout lysates as definitive controls3

• Comparison with established markers:

  • Co-stain with E-cadherin or EpCAM for epithelial verification

  • Signals should be mutually exclusive with mesenchymal markers

By integrating these approaches, researchers can confidently distinguish specific KRT8 detection from technical artifacts or cross-reactivity with other keratins 3 .

What are the common pitfalls in quantifying KRT8 expression levels?

Accurate quantification of KRT8 expression faces several challenges:

• Western blot quantification issues:

  • Saturation of signal leads to underestimation of differences

  • Solution: Use gradient loading to establish linear range

  • Normalize to loading controls unaffected by experimental conditions

• Immunostaining quantification pitfalls:

  • Threshold selection bias in image analysis

  • Batch-to-batch staining variability

  • Solution: Include calibration controls in each batch and blind analysis

• Flow cytometry considerations:

  • Adequate permeabilization is critical for intracellular KRT8

  • Compensation required when multiplexing

  • Solution: Use fluorescence minus one (FMO) controls

• Post-translational modifications:

  • Phosphorylation or other modifications may affect antibody binding

  • Solution: Use total protein stains as normalization

• Filament solubility differences:

  • Different extraction methods may yield varying amounts of KRT8

  • Solution: Use multiple extraction protocols to capture all pools

• Sample heterogeneity:

  • Varying epithelial content between samples

  • Solution: Normalize to epithelial content using additional markers

  • Consider single-cell approaches for heterogeneous samples

A robust quantification approach combines multiple techniques, appropriate controls, and statistical validation to ensure reliable measurements of KRT8 expression changes3 .

How do post-translational modifications of KRT8 affect antibody binding and function?

Post-translational modifications (PTMs) of KRT8 significantly impact both antibody recognition and functional properties:

• Phosphorylation effects:

  • Ser23, Ser73, and Ser431 are major phosphorylation sites

  • Phosphorylation during stress and mitosis reorganizes filament structure

  • Phospho-specific antibodies can monitor these events

  • Conventional antibodies may show reduced binding to heavily phosphorylated KRT8

• Glycosylation considerations:

  • O-GlcNAcylation occurs at multiple KRT8 sites

  • May compete with phosphorylation (molecular switch)

  • Can affect antibody accessibility to nearby epitopes

  • Important for filament organization and solubility

• Acetylation impacts:

  • Affects KRT8 stability and organization

  • May alter antibody binding depending on epitope location

  • Consider using deacetylase inhibitors to stabilize acetylation for consistent detection

• Sample preparation implications:

  • Phosphatase treatment may enhance detection if phosphorylation masks epitopes

  • Inclusion of PTM-preserving inhibitors crucial for studying modified forms

  • Consider native conditions to maintain physiologically relevant modifications

• Functional consequences:

  • PTMs regulate KRT8 solubility, filament organization, and protein interactions

  • Stress-induced phosphorylation is particularly important in disease contexts

  • PTM status affects KRT8's role as a stress protector in cells

Understanding the PTM status of KRT8 in your experimental system is crucial for accurate interpretation of functional studies and for selecting appropriate antibodies that either recognize or are independent of specific modifications .

What considerations are important when studying KRT8 in cancer research?

Cancer research involving KRT8 requires attention to several critical factors:

• Tumor heterogeneity considerations:

  • KRT8 expression can vary within tumors, requiring sampling of multiple regions

  • Single-cell approaches may reveal subpopulations with different expression

  • Correlation with differentiation status and other markers improves interpretation

• Interpretation in different cancer types:

  • Adenocarcinomas typically maintain KRT8/18 expression

  • Loss may indicate epithelial-mesenchymal transition (EMT)

  • Aberrant expression in non-epithelial cancers may have prognostic significance

• Circulating biomarker potential:

  • Released KRT8 and anti-KRT8 antibodies detected in cancer patients' serum

  • May serve as minimally invasive biomarkers

  • Correlate with clinical parameters for validation

• Functional aspects beyond detection:

  • KRT8 mutations linked to liver and pancreatic disease predisposition

  • Interactions with drug resistance pathways

  • Role in protecting cells from apoptosis under stress conditions

• Technical approach selection:

  • IHC for spatial information and tumor classification

  • Western blot for quantitative expression differences

  • serum ELISA for circulating KRT8 or anti-KRT8 antibodies

  • Co-detection with KRT18 for filament integrity assessment

Recent studies have identified CK8 as a tumor antigen using serological screening techniques like SEREX and AMIDA, with elevated levels of CK8-specific antibodies observed in patients with head and neck cancer. This suggests potential applications in cancer monitoring and diagnosis beyond simple tissue identification .

How are KRT8 antibodies being utilized in circulating tumor cell detection?

KRT8 antibodies are increasingly valuable in circulating tumor cell (CTC) detection strategies:

• CTC enrichment and identification:

  • KRT8 serves as a critical epithelial marker for identifying CTCs of epithelial origin

  • Often used in combination with other epithelial markers (EpCAM, KRT18, KRT19)

  • Helps distinguish CTCs from blood cells which are KRT8-negative

  • Enables monitoring of disease progression and treatment response

• Methodological approaches:

  • Immunomagnetic separation using antibody-coated beads

  • Microfluidic devices with immobilized antibodies

  • Flow cytometry following red blood cell lysis

  • Filtration methods followed by immunocytochemical confirmation

• EMT considerations:

  • KRT8 expression may be downregulated during EMT

  • Combined use of epithelial and mesenchymal markers improves CTC detection

  • Serial monitoring may reveal phenotypic shifts during disease progression

• Clinical applications:

  • Prognostic value: CTC counts correlate with outcomes in multiple cancer types

  • Treatment monitoring: Changes in CTC numbers indicate treatment efficacy

  • Personalized medicine: CTCs enable genetic/phenotypic analysis for therapy selection

• Technical challenges:

  • Fixation and permeabilization must be optimized for rare cell detection

  • Antibody specificity crucial to avoid false positives

  • Autofluorescence can interfere with detection in some platforms

The integration of KRT8 antibodies in CTC detection platforms represents a growing application with significant clinical potential for minimally invasive cancer monitoring .

What is the role of KRT8 in stress responses and how can antibodies help study this?

KRT8 plays critical roles in cellular stress responses that can be investigated using specialized antibody approaches:

• Stress-induced phosphorylation:

  • Phospho-specific antibodies detect stress-activated sites (Ser73, Ser431)

  • Ser73 phosphorylation by p38 MAPK and JNK during stress

  • Ser431 phosphorylation by ERK during mitosis

  • These modifications regulate filament reorganization and solubility

• Methodological approaches:

  • Dual staining with total and phospho-specific KRT8 antibodies

  • Time-course studies following stress induction

  • Co-localization with stress granules or other stress-response structures

  • Proximity ligation assays to detect stress-induced protein interactions

• Protective functions:

  • KRT8 provides mechanical resilience during stress

  • Serves as a phosphate "sponge" to buffer kinase activity

  • Protects cells from apoptosis under various stressors

  • These functions can be probed with domain-specific antibodies

• Disease relevance:

  • Liver disease: KRT8 variants predispose to liver injury

  • Inflammatory bowel disease: KRT8 mutations increase susceptibility

  • Cancer: Altered KRT8 phosphorylation affects drug responses

• Experimental design considerations:

  • Include appropriate stress conditions (oxidative, mechanical, chemical)

  • Use phosphatase inhibitors to preserve modification state

  • Compare acute vs. chronic stress responses

  • Consider genetic approaches (phospho-mutants) to complement antibody studies

The application of specific KRT8 antibodies, particularly those recognizing post-translational modifications, provides valuable insights into how intermediate filaments participate in cellular stress responses and may reveal therapeutic opportunities in diseases involving dysregulated stress handling .

How do knockout validation approaches improve KRT8 antibody reliability?

Knockout validation has revolutionized antibody validation, particularly for challenging targets like KRT8:

• CRISPR-based validation methodology:

  • Generation of cell lines with both KRT8 alleles knocked out

  • Confirmation of knockout at DNA level (sequencing)

  • Preparation of matched knockout and parental cell lysates

  • Side-by-side testing of antibodies against both lysates3

• Validation criteria:

  • Specific antibody shows signal in parental lysate but not in knockout

  • Loading controls confirm equal protein loading

  • Signal intensity appropriate for expression level

  • Accurate molecular weight detection

• Advantages over traditional methods:

  • Provides definitive negative control (complete absence of target)

  • Controls for all potential cross-reactive proteins

  • Evaluates antibody performance in relevant cellular context

  • More reliable than peptide competition or overexpression systems

• Implementation approaches:

  • Commercial KO cell lysates available for common targets

  • Custom CRISPR KO generation for specialized applications

  • Repository sharing of validated KO lines

  • Multi-antibody testing against standard KO resources

• Impact on research quality:

  • Reduction in false discoveries from cross-reactive antibodies

  • Enhanced reproducibility across laboratories

  • Greater confidence in complex applications (ChIP-seq, proteomics)

  • Standardization of validation criteria

The knockout validation approach represents a significant advance in antibody validation, with organizations like OriGene creating extensive libraries of CRISPR knockout lysates that enable rigorous validation of antibodies including those targeting KRT83.

What are the current challenges and future directions in KRT8 antibody development?

The field of KRT8 antibody development faces several challenges and opportunities:

• Current limitations:

  • Cross-reactivity with other keratins (particularly KRT7)

  • Batch-to-batch variability affecting reproducibility

  • Limited epitope diversity in available antibodies

  • Inadequate validation for specialized applications

• Emerging technologies:

  • Recombinant antibody production for higher consistency

  • Single-domain antibodies (nanobodies) for improved access to filament structures

  • Multiplexed validation platforms (CyTOF, imaging mass cytometry)

  • AI-assisted epitope prediction and antibody design

• Application-specific needs:

  • Conformation-specific antibodies for filament assembly states

  • Improved membrane-permeant antibodies for live-cell studies

  • Degradation-resistant antibodies for harsh extraction conditions

  • Standardized quantitative calibration systems

• Translational directions:

  • Companion diagnostic development for cancer therapies

  • Point-of-care tests for KRT8 or anti-KRT8 antibodies in patient samples

  • Targeted drug delivery using KRT8 antibodies in epithelial cancers

  • Biomarker qualification efforts for regulatory approval

• Scientific frontiers:

  • Understanding the role of KRT8 in disease progression

  • Exploration of non-canonical KRT8 functions

  • Investigation of KRT8's role in cellular mechanical properties

  • Characterization of the KRT8 interactome under normal and stress conditions

Advances in antibody engineering, validation methodologies, and biological understanding of KRT8 function will drive continued improvement in research tools and potential diagnostic applications3 .